Cox Distinguished Lecture Series

Abstract. Synthetic biology is the design and construction of new biological entities such as enzymes, genetic circuits, and cells or the redesign of existing biological systems. Synthetic biology builds on the advances in molecular, cell, and systems biology and seeks to transform biology in the same way that synthesis transformed chemistry and integrated circuit design transformed computing. The element that distinguishes synthetic biology from traditional molecular and cellular biology is the focus on the design and construction of core components (parts of enzymes, genetic circuits, metabolic pathways, etc.) that can be modeled, understood, and tuned to meet specific performance criteria, and the assembly of these smaller parts and devices into larger integrated systems that solve specific problems. Just as engineers now design integrated circuits based on the known physical properties of materials and then fabricate functioning circuits and entire processors (with relatively high reliability), synthetic biologists will soon design and build engineered biological systems.

We have used synthetic biology to create inexpensive, effective, anti-malarial drugs. Currently, malaria infects 300-500 million people and causes 1-2 million deaths each year, primarily children in Africa and Asia. One of the principal obstacles to addressing this global health threat is a lack of effective, affordable drugs. The chloroquine-based drugs that were used widely in the past have lost effectiveness because the Plasmodium parasite which causes malaria has become resistant to them. The faster-acting, more effective artemisinin-based drugs - as currently produced from plant sources - are too expensive for large-scale use in the countries where they are needed most. The development of this technology will eventually reduce the cost of artemisinin-based combination therapies significantly below their current price. To reduce the cost of these drugs and make them more widely available, we have used synthetic biology to engineer microorganisms to produce artemisinin from renewable resources.

Having successfully completed the artemisinin work, we are now engineering the metabolism of the same microorganisms (Escherichia coli and Saccharomyces cerevisiae) for production of advanced biofuels. Unlike ethanol, these biofuels will have the full fuel value of petroleum-based biofuels, will be transportable using existing infrastructure, and can be used in existing automobiles and airplanes. These biofuels will be produced from natural biosynthetic pathways that exist in plants and a variety of microorganisms. Large-scale production of these fuels will reduce our dependence on petroleum and reduce the amount of carbon dioxide released into the atmosphere, while allowing us to take advantage of our current transportation infrastructure.

Biography. Jay Keasling is a Professor of Bioengineering and Chemical Engineering at the University of California, Berkeley and the Acting Deputy Director and CEO of the Joint BioEnergy Institute at Lawrence Berkeley National Lab. His research is organized around three primary themes: synthetic biology, systems biology and environmental biotechnology. He has been associated with institutions throughout the country such as the Massachusetts Institute of Technology, Michigan State University, Johns Hopkins and Stanford University. He has published over 150 articles. For his breakthroughs in the field of synthetic biology, including treatments for malaria, AIDS, and cancer as well as discoveries of new fuel resources, Discover Magazine awarded Professor Keasling with its first-ever Scientist of the Year award in 2006. On the lighter side, Stephen Colbert accused him of being a mad scientist in his Colbert Report appearance last March.

Dr. Keasling's lecture is jointly sponsored by the International Center for Advanced Renewable Energy and Sustainability (I-CARES).